Tirbanibulin for Pediatric Warts
Part of paid clinical trials in New City, New York.
- Sponsor
- The Skin Center Dermatology Group
- Study ID
- NCT06791525
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Warts Hand
Eligibility Criteria
- Sex
- ALL
- Age
- 8 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tirbanibulin ointment 1% — DRUGTopical application
Study Details
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Apr 2026
- Primary completion
- Nov 1, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Topical treatment armTopical medication self-applied
Primary Outcome Measure
Resolution [ Time Frame: 2 months aftre completion of 4 or less treatment cycles ]
Central Contacts
- Peter Friedman, MD, PhD8453520500
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Skin Center Dermatology Group | New City | New York | 10956 | Peter Friedman, Principal Investigator, MD PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New City, NY
By research site